Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

ImClone Terminates Cancer Drug Development Deal with UCB

  • ImClone Systems reported that it has opted-out of its development agreement with UCB related to UCB’s Phase II non-small-cell-lung cancer therapy.

    UCB retains the freedom to operate rights globally for CDP-791 and some of ImClone's intellectual property pertaining to vascular endothelial growth factor receptor-2 (VEGFR-2). ImClone will receive royalties on future sales of CDP-791.

    Melanie Lee, executive vp, R&D, UCB expects to have results from the Phase IIa study around April. CDP-791 is UCB's PEGylated diFab antibody that inhibits the function of a signaling pathway that plays a role in the formation of blood vessels in tumors by blocking VEGFR-2 from binding to molecules that stimulate its activation.

    ImClone says it will focus its resources on the development of its own antibody candidate targeting VEGFR-2. "We are on target to complete Phase I studies of IMC-1121B on several administration schedules in the first half of 2007 and intend to focus significant efforts on developing this promising VEGFR-2 blocking antibody," remarks Eric Rowinsky, M.D., CMO and senior vp of ImClone.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »